Skip to content
Search

Latest Stories

UKHSA Chief Executive warns of further outbreaks of measles

Around 216 confirmed cases and 103 probable cases have been recorded in the West Midlands since October 2023, mostly in Birmingham

The UK Health Security Agency’s (UKHSA) Chief Executive, Professor Dame Jenny Harries has expressed concern that measles outbreak could spread to other towns and cities unless urgent action is taken to increase Measles, Mumps and Rubella (MMR) vaccination uptake in areas at greatest risk.


The virus can spread very easily among those who are unvaccinated, especially in nurseries and schools, she said on Friday (19 January) during a visit to Birmingham to review the ongoing work to contain the spread of the disease.

A rapid rise in cases has been seen in the West Midlands since 1 October 2023, with 216 confirmed cases and 103 probable cases recorded till 18 January.

The majority of the cases (around 80 per cent) were reported from Birmingham, with about 10 per cent in Coventry, mostly affecting children aged under 10 years.

Dame Jenny is calling on all local areas to increase MMR vaccine uptake rates in communities across the country.

She said: “Colleagues across the West Midlands have worked tirelessly to try to control the outbreak, but with vaccine uptake in some communities so low, there is now a very real risk of seeing the virus spread in other towns and cities.”

She is encouraging parents to ensure that their children get the MMR vaccine to protect them from measles, which can sometimes lead to life changing complications.

“Two doses of the MMR vaccine give lifelong protection and it’s never too late to catch up,” Dame Jenny said.

Furthermore, Dame Jenny highlighted that urgent action is needed to boost MMR uptake across communities where vaccine uptake is low.

The MMR vaccination is provided as part of the NHS Routine Childhood Immunisation Programme – with one dose offered at one year and another second dose at 3 years 4 months. It is a safe and effective way of protecting against measles, as well as mumps and rubella.

More For You

Prostate cancer: At-home saliva test could save NHS £500 million annually

PRS saliva test can identify prostate cancer that was missed by an MRI scan

Photo credit: gettyimages

Prostate cancer: Spit test better than blood test in spotting men at highest risk

A simple at-home spit test could help detect prostate cancer earlier, saving the NHS around £500 million a year, according to new research published in the New England Journal of Medicine.

Funded by the National Institute for Health and Care Research (NIHR), the study found that the DNA-based saliva test was more accurate than the current prostate-specific antigen (PSA) blood test in identifying men at risk of developing prostate cancer.

Keep ReadingShow less
RPS launches innovative new learning resources for members

With RPS Learn, pharmacists can develop a new skill or improve their understanding of practice or a clinical topic.

Gettyimages

RPS launches new learning resources to boost career development for members

The Royal Pharmaceutical Society (RPS) has launched a new online learning platform designed to support the practice, development and career advancement of its members.

The new platform, called RPS Learn, offers a diverse range of bite-size learning content, available on-demand, catering to all levels — from introductory to advanced and specialist —combining new content with RPS's renowned expertise in education and training to achieve excellence for learners.

Keep ReadingShow less
NICE approves AstraZeneca’s twice-a-day tablet ‘capivasertib’ for advanced breast cancer

HR-positive, HER2-negative advanced breast cancer is currently incurable, and treatment aims to slow progression and prolong life

Gettyimages

NICE approves twice-a-day tablet for advanced breast cancer

Every year, thousands of people with hormone receptor (HR)-positive HER2-negative breast cancer could benefit from a new twice-a-day tablet, now set to be funded immediately through the Cancer Drugs Fund.

The National Institute for Health and Care Excellence (NICE) has approved the use of capivasertib (also known as Truqap), in combination with fulvestrant, as an option for around 1,100 adults with HR-positive HER2-negative breast cancer that has certain genetic mutations and has spread.

Keep ReadingShow less
ABPI and government fast-track VPAG scheme review to address high medicine payment rates

The 2025 VPAG payment rate for newer medicines has been set at 22.9 per cent.

Photo credit: gettyimages

Review of 2024 VPAG scheme to be completed by June

The Association of the British Pharmaceutical Industry (ABPI) and the government have agreed to bring forward a planned review of the 2024 Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG), originally scheduled for autumn 2025.

The review is expected to be completed in June 2025, aligning with the anticipated release of the government’s 10-year NHS Plan and the Life Sciences Sector Plan as part of the broader industry strategy this summer.

Keep ReadingShow less
AAH upgrades ordering portal, making procurement easier for pharmacies

AAH Cascade compares prices and availability across suppliers

AAH Warehouse

AAH upgrades ordering portal to improve product visibility

Leading pharmaceutical wholesaler AAH Pharmaceuticals Ltd has introduced new digital functionalities to AAH Cascade, its independently managed ordering portal, making procurement easier and more cost-effective for pharmacies.

AAH Cascade compares product prices and availability across multiple suppliers, eliminating the need for manual searches.

Keep ReadingShow less